Table 2.
Outcomesa of Cervical Biopsies in 3 Managed Care Plans, Overall and by Age Group, as a Percentage of All Cervical Biopsies (1998-2007)b
| Age group | Number of biopsies | Result, % | ||||||
|---|---|---|---|---|---|---|---|---|
| Normal | CIN-1 | CIN-2 | CIN-3/carcinoma in situ | Squamous cell carcinoma | Adeno-carcinoma/AIS | Unknown | ||
| 21-30 | 10,598 | 56.9 | 31.8 | 6.3 | 3.1 | 0.1 | 0.1 | 1.8 |
| 31-40 | 10,038 | 75.4 | 15.7 | 3.7 | 2.8 | 0.3 | 0.3 | 1.8 |
| 41-50 | 14,292 | 88.1 | 7.4 | 1.2 | 1.0 | 0.3 | 0.3 | 1.8 |
| 51-60 | 9,883 | 90.8 | 4.4 | 0.8 | 0.6 | 0.3 | 0.3 | 2.7 |
| 61-65 | 1,846 | 89.9 | 3.8 | 0.5 | 0.7 | 0.5 | 0.9 | 3.7 |
| Overall | 46,657 | 78.9 | 13.9 | 2.8 | 1.8 | 0.2 | 0.3 | 2.0 |
Abbreviations: AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma.
a
For women who underwent multiple biopsies on the same date, the most severe result was selected using the following order: adenocarcinoma/AIS, SCC, CIN-3/SSC in situ, CIN-2, CIN-1, normal, and unknown.
b
Excluded 824 women with prior human papillomavirus vaccination; excluded 17,065 records with treatment received within 10 days before or after the pathology collection date.